Use of rituximab in NHL malt type pregnant in I° trimester for two times

Abstract

Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. Howe ver, several cases of pregnant women being treated with rituximab are reported herein; an exception is often made in cases with grave illness.

Keywords

• ituximab
• pregnancy and rituximab
• non-hodgkin lymphoma